ArticleGene therapy2005
Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Single-cell analysis reveals shared and distinct molecular signatures in brain organoid models of neurodegeneration and neuroinflammation.Alzheimer's research & therapy · 2025Article
- The role of midkine in health and disease.Frontiers in immunology · 2023Review
- Midkine-A novel player in cardiovascular diseases.Frontiers in cardiovascular medicine · 2022Review
- Extracellular DJ-1 induces sterile inflammation in the ischemic brain.PLoS biology · 2021Article
- Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury.Frontiers in neurology · 2020Review
- Midkine's Role in Cardiac Pathology.Journal of cardiovascular development and disease · 2017Article
- Midkine in repair of the injured nervous system.British journal of pharmacology · 2014Review
- Midkine in nephrogenesis, hypertension and kidney diseases.British journal of pharmacology · 2014Review
- Therapeutic potential of midkine in cardiovascular disease.British journal of pharmacology · 2014Review
- Loss of heparin-binding protein prevents necrotizing glomerulonephritis: first clues hint at plasminogen activator inhibitor-1.International urology and nephrology · 2013Review
- The effects of early exercise on brain damage and recovery after focal cerebral infarction in rats.Acta physiologica (Oxford, England) · 2011Article
- Midkine: a promising molecule for drug development to treat diseases of the central nervous system.Current pharmaceutical design · 2011Review
- Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2010Review
- IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis.Gene therapy · 2008Article
- Absence of an intrathecal immune reaction to a helper-dependent adenoviral vector delivered into the cerebrospinal fluid of non-human primates.Gene therapy · 2008Article
- Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.The American journal of pathology · 2006Article
- Human gene therapy and imaging in neurological diseases.European journal of nuclear medicine and molecular imaging · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy may be a promising approach for treatment of brain ischemia. In this study, we examined the effect of postischemic gene transfer of midkine, a heparin-binding neurotrophic factor, using a focal brain ischemia model with the photothrombotic occlusion method. At 90 min after induction of brain ischemia in spontaneously hypertensive rats, a replication-deficient recombinant adenovirus encoding mouse midkine (AdMK, n=7) or a control vector encoding beta-galactosidase (Adbetagal, n=7) was injected into the lateral ventricle ipsilateral to ischemia. At 2 days after ischemia, we determined infarct volume by 2,3,5-triphenyltetrazolium chloride staining. There were no significant differences in cerebral blood flow 1 h after ischemia between AdMK and Adbetagal groups. Infarct volume of AdMK group was 51+/-27 mm3, which was significantly smaller than that of Adbetagal group (86+/-27 mm3, P<0.05). TUNEL-positive and cleaved caspase-3-positive cells in the periischemic area of AdMK-treated rats were significantly fewer than those in Adbetagal-treated rats, suggesting that the reduction of infarct volume by midkine was partly mediated by its antiapoptotic action. Thus, gene transfer of midkine to the ischemic brain may be effective in the treatment of brain ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.